Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction

Troublemaking mutations: Clonal hematopoiesis for the prediction of prognosis in ST-segment elevation myocardial infarction

“…In summary, the novel results reported by Wang et al 5 have important implications for our understanding of the prognostic value of CHIP mutations. This work expands the mounting body of evidence linking CHIP to CVD, and reinforces the notion that the detection of CHIP may in the future aid decision-making in the clinical management of the growing population of patients who survive a MI.…”

“…In this issue of EBioMedicine, Wang et al 5 shed light on the clinical implications of CHIP in patients affected by a myocardial infarction with ST-segment elevation (STEMI), a common acute clinical manifestation of coronary artery disease that is associated with increased risk of death and ischemic heart failure (HF) development. The authors performed deep targeted sequencing in a cohort of 485 patients with STEMI (median age of 62 years) to assess the prevalence and prognostic value of CHIP in this setting.…”

“…A major strength of the work by Wang et al 5 is the use of a deep sequencing strategy, which allows for greater sensitivity in the detection of CHIP with relatively small mutant clones (e.g. VAF < 5%) than the whole exome/genome approaches used in previous larger studies.…”

Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors: an analysis of the UK Biobank

“…Previous research looking at mutation driven CH have correlated mutations in DNMT3A and TET2 with chronic heart failure in patients with STEMI (n=485). 35 In another study including approximately 50 000 samples with exome sequencing data, Zekavat et al 26 found that carriers of CHIP mutations had higher risks of peripheral artery disease. Third, when considering cancer survivors, it is possible that cancer-directed treatments may have perpetuated the influence of mCA on outcomes.…”

Ciprofol attenuates the isoproterenol-induced oxidative damage, inflammatory response and cardiomyocyte apoptosis

“…Epidemiological data showed that 17.8 million people worldwide have died of cardiovascular diseases every year, corresponding to 330 million years of life loss and 35.6 million years of disabled life ( GBD, 2018 ; Mensah et al, 2019 ; Shi et al, 2022 ). Myocardial infarction is the most lethal manifestation of cardiovascular diseases, characterized by the reduction of blood perfusion in the heart, which leads to a decrease in the oxygen supply of the heart and then results in myocardial damage involving both necrosis and apoptosis of the heart muscle ( de Lemos et al, 2019 ; Roumeliotis et al, 2021 ; Huse et al, 2022 ; Lan et al, 2022 ; Wang et al, 2022 ). Since cardiomyocytes are terminally differentiated cells and do not regenerate, preventing cardiomyocyte injury and loss is a promising strategy for myocardial infarction.…”